Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.

The CREB (cAMP responsive element binding protein) binding protein (CBP) and its homolog EP300 have emerged as new therapeutic targets for the treatment of cancer and inflammatory diseases. Here we report the identification, optimization and evaluation of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 inhibitors starting from fragment-based virtual screening (FBVS). A cocrystal structure of the inhibitor (22e) in complex with CBP provides a solid structural basis for further optimization. The most potent compound 32h binds to the CBP bromodomain and has an IC50 value of 0.037 μM in the AlphaScreen assay which was 2 times more potent than the reported CBP bromodomain inhibitor SGC-CBP30 in our hands. 32h also exhibit high selectivity for CBP/EP300 over other bromodomain-containing proteins. Notably, the ester derivative (29h) of compound 32h markedly inhibits cell growth in several prostate cancer cell lines including LNCaP, 22Rv1 and LNCaP derived C4-2B. Compound 29h suppresses the mRNA expression of full length AR (AR-FL), AR target genes and other oncogene in LNCaP cells. 29h also reduces the expression of PSA, the biomarker of prostate cancer. CBP/EP300 inhibitor 29h represents a promising lead compound for the development of new therapeutics for the treatment of castration-resistant prostate cancer.

[1]  R. Andersen,et al.  An androgen receptor N-terminal domain antagonist for treating prostate cancer. , 2013, The Journal of clinical investigation.

[2]  K. Lam,et al.  ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer , 2016, Nature Medicine.

[3]  C. Nguyên,et al.  Small molecule inhibition of CBP/catenin interactions eliminates drug resistant clones in acute lymphoblastic leukemia , 2013, Oncogene.

[4]  Yan Zhang,et al.  Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation. , 2016, Journal of medicinal chemistry.

[5]  Ernest Martinez,et al.  Dual Regulation of c-Myc by p300 via Acetylation-Dependent Control of Myc Protein Turnover and Coactivation of Myc-Induced Transcription , 2005, Molecular and Cellular Biology.

[6]  A. Caflisch,et al.  Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain. , 2016, Journal of medicinal chemistry.

[7]  N. L. La Thangue,et al.  p300/CBP proteins: HATs for transcriptional bridges and scaffolds. , 2001, Journal of cell science.

[8]  Y. Leblanc,et al.  Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637). , 2016, ACS medicinal chemistry letters.

[9]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[10]  Andrew J. Bannister,et al.  Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. , 2015, Cancer research.

[11]  Yu Song,et al.  Identification of N-phenyl-2-(N-phenylphenylsulfonamido)acetamides as new RORγ inverse agonists: Virtual screening, structure-based optimization, and biological evaluation. , 2016, European journal of medicinal chemistry.

[12]  Karen E Gascoigne,et al.  Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300. , 2016, Journal of medicinal chemistry.

[13]  Mitsuhiko Ikura,et al.  Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: structural and functional versatility in target recognition , 2013, Cellular and Molecular Life Sciences.

[14]  J. Bouchal,et al.  Transcriptional coactivators p300 and CBP stimulate estrogen receptor‐beta signaling and regulate cellular events in prostate cancer , 2011, The Prostate.

[15]  C. Caldas,et al.  p300/CBP and cancer , 2004, Oncogene.

[16]  A. Caflisch,et al.  The "Gatekeeper" Residue Influences the Mode of Binding of Acetyl Indoles to Bromodomains. , 2016, Journal of medicinal chemistry.

[17]  G. Hatzivassiliou,et al.  Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition* , 2016, The Journal of Biological Chemistry.

[18]  Michael D. Nyquist,et al.  Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies , 2015, Nucleic acids research.

[19]  J. Direnzo,et al.  p300 is a component of an estrogen receptor coactivator complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Caflisch,et al.  Discovery of CREBBP Bromodomain Inhibitors by High-Throughput Docking and Hit Optimization Guided by Molecular Dynamics. , 2016, Journal of medicinal chemistry.

[21]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[22]  R. Vessella,et al.  Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer , 2013, Oncotarget.

[23]  S. Knapp,et al.  Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains , 2014, Journal of the American Chemical Society.

[24]  David E. Williams,et al.  Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. , 2010, Cancer cell.

[25]  Hannu Raunio,et al.  Prodrugs—from Serendipity to Rational Design , 2011, Pharmacological Reviews.

[26]  G. Raj,et al.  EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer , 2015, Oncotarget.

[27]  Zhaohui S. Qin,et al.  Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.

[28]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[29]  N. Engedal,et al.  CREB Binding Protein Is a Coactivator for the Androgen Receptor and Mediates Cross-talk with AP-1* , 1998, The Journal of Biological Chemistry.

[30]  A. Mitra,et al.  Prodrug strategies in ocular drug delivery. , 2012, Medicinal chemistry (Shariqah (United Arab Emirates)).

[31]  K. Siegmund,et al.  Selective Roles for cAMP Response Element-binding Protein Binding Protein and p300 Protein as Coregulators for Androgen-regulated Gene Expression in Advanced Prostate Cancer Cells* , 2011, The Journal of Biological Chemistry.

[32]  Yan Zhang,et al.  The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation. , 2016, Bioorganic & medicinal chemistry.

[33]  E. Verdin,et al.  Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity , 2016, eLife.

[34]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[35]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[36]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[37]  Yan Zhang,et al.  Discovery of 2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide derivatives as new RORγ inhibitors using virtual screening, synthesis and biological evaluation. , 2014, European journal of medicinal chemistry.

[38]  Karen E Gascoigne,et al.  Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma , 2016, eLife.

[39]  S. Knapp,et al.  Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors. , 2016, Journal of medicinal chemistry.

[40]  N. Pannu,et al.  REFMAC5 for the refinement of macromolecular crystal structures , 2011, Acta crystallographica. Section D, Biological crystallography.

[41]  P. Cole,et al.  Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112. , 2016, Biochemistry.

[42]  M. Montminy,et al.  Role of CBP/P300 in nuclear receptor signalling , 1996, Nature.

[43]  S. Knapp,et al.  [1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of Diverse Bromodomains , 2013, Journal of medicinal chemistry.

[44]  Kevin Lee,et al.  Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic Opportunities. , 2015, Chemistry & biology.

[45]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[46]  L. Tsai,et al.  Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Manfredi,et al.  Target structure-based discovery of small molecules that block human p53 and CREB binding protein association. , 2006, Chemistry & biology.

[48]  Stefan Knapp,et al.  A Series of Potent CREBBP Bromodomain Ligands Reveals an Induced-Fit Pocket Stabilized by a Cation–π Interaction** , 2014, Angewandte Chemie.